摘要
目的探讨阿帕替尼化疗治疗二线治疗失败晚期卵巢癌患者的临床疗效。方法选取2017年2月至2019年3月间北京市平谷区医院收治的二线治疗失败的44例晚期卵巢癌患者。根据治疗方法不同进行分组。其中,采用以紫杉类或蒽环类为基础化疗方案治疗的22例患者纳入对照组,在紫杉类或蒽环类的基础上口服阿帕替尼治疗的22例患者纳入观察组。两组患者连续治疗6个化疗周期,通过比较两组患者临床有效性及不良反应的发生率。结果观察组的临床有效性为59.1%,高于对照组的50.0%,差异有统计学意义(P<0.05)。两组患者均坚持完成了6个化疗周期,其中两组患者均出现了腹泻、高血压、手足综合征、恶心呕吐以及白细胞减少等不良反应,等级为Ⅰ~Ⅲ级,未出现严重的不良反应事件,两组患者的各不良反应发生率比较,差异无统计学意义(P>0.05)。结论将阿帕替尼联合化疗运用于二线治疗失败晚期卵巢癌患者的治疗中,可以提高其临床有效率,患者可以耐受其治疗的不良反应,可以运用于临床。
Objective To explore the clinical efficacy of apatinib combined with chemotherapy in patients with advanced ovarian cancer who have failed to achieve response in the second-line treatment.Methods From February 2017 to March 2019,44 patients with advanced ovarian cancer who failed to achieve response in the second-line treatment were selected at Beijing Pinggu District Hospital.They were randomly divided into an observation group and a control group according to the therapy they received with22 patients in each group.The observation group was administered apatinib besides taxanes or anthracyclines-based chemotherapy.The control group was only given taxanes or anthracyclines-based chemotherapy.The two groups were continuously treated for 6 cycles.The clinical effectiveness and the incidence of adverse reactions were compared between the two groups.Results The clinical effectiveness was 59.1%in the observation group which was higher than 50.0%of the control group(P<0.05).Patients in both groups completed the 6 cycles of chemotherapy and adverse reactions occurred in 2 patients including diarrhea,hypertension,hand-foot syndrome,nausea and vomiting and leukopenia grade 1 to 3.No serious adverse reaction was observed in either group.There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Apatinib as second-line therapy for advanced ovarian cancer can improve the clinical effectiveness.The adverse reactions are tolerable.It deserves the clinical expansion.
作者
刘海明
崔冬梅
李永颜
LIU Hai-ming;CUI Dong-mei;LI Yong-yan(Department of Oncohaematology,Beijing Pinggu District Hospital,Beijing 101200,China)
出处
《中国肿瘤临床与康复》
2020年第3期316-318,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
阿帕替尼
二线治疗失败
晚期卵巢肿瘤
临床疗效
不良反应
Apatinib
Second-line treatment failure
Advanced ovarian neoplasms
Clinical efficacy
Adverse reactions
